Back to News
Market Impact: 0.15
Capricor To Present 24-Month HOPE-3 Data At WMS 2026
Source: Nasdaq
Healthcare & Biotech
Capricor Therapeutics will present new data from its Phase 3 HOPE-3 trial and open-label extension of deramiocel at the World Muscle Society Congress in Hiroshima, Japan, from September 29 to October 3, 2026. The announcement provides a future clinical-data catalyst but includes no efficacy, safety, regulatory, or financial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
CAPR0.20
More News
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Wells Fargo raises Abbvie stock price target to $340 on pipeline
- Wells Fargo raises Regeneron stock price target to $925 on execution
- Deutsche Bank downgrades Novartis stock rating to sell on valuation
- Apple, Marriott International and 3 Stocks to Watch Heading Into Monday
- Soaring health insurance costs are quietly preventing wages from rising higher, while workers also shoulder a larger share of premiums, economist says